JAFRAL is proud to be a GMP manufacturing partner of a consortium/project for first clinical trial on combined electrochemotherapy with gene therapy with Interleukin-12 (IL-12) to improve/enhance local and systemic response to skin tumor treatment.

The operation is partly financed by the European Union, from the European Regional Development Fund (ERDF) and Slovenian Ministry of Education, Science and Sport. The operation is carried out in the framework of the Operational Program for the Implementation of the European Cohesion Policy for the period 2014-2020.